Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Debt (2020 - 2024)

Syndax Pharmaceuticals (SNDX) has disclosed Total Debt for 5 consecutive years, with $343.7 million as the latest value for Q4 2024.

  • For Q4 2024, Total Debt changed N/A year-over-year to $343.7 million; the TTM value through Dec 2024 reached $343.7 million, changed N/A, while the annual FY2024 figure was $343.7 million, N/A changed from the prior year.
  • Total Debt hit $343.7 million in Q4 2024 for Syndax Pharmaceuticals, up from $20.2 million in the prior quarter.
  • Across five years, Total Debt topped out at $343.7 million in Q4 2024 and bottomed at $19.8 million in Q1 2020.
  • Average Total Debt over 4 years is $49.5 million, with a median of $20.1 million recorded in 2020.
  • Year-over-year, Total Debt grew 2.36% in 2021 and then dropped 0.92% in 2022.
  • Syndax Pharmaceuticals' Total Debt stood at $20.1 million in 2020, then fell by 0.18% to $20.1 million in 2021, then increased by 0.62% to $20.2 million in 2022, then soared by 1600.89% to $343.7 million in 2024.
  • According to Business Quant data, Total Debt over the past three periods came in at $343.7 million, $20.2 million, and $20.0 million for Q4 2024, Q2 2022, and Q1 2022 respectively.